Acta Pharmaceuticals, Inc. — Form D/A
Acta Pharmaceuticals, Inc. of BOSTON, MA, a company, filed a Form D amendment with the SEC on 2024-04-22. The offering totals $17.5M, of which $13.4M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2024-04-22
- Form: D/A
- Accession: 0001972861-24-000001
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $17.5M
- Amount sold: $13.4M
- Remaining: $4.1M
- Investors: 29
- Date of first sale: 2023-03-29
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-478258
Issuer
- Name: Acta Pharmaceuticals, Inc.
- CIK: 0001972861
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2022
- Address: 292 NEWBURY STREET, BOSTON, MA, 02115
- Phone: 8579302282
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| George Alex | Director | Boston, MA |
| Thierry Porte | Director | ST. HELIER, Y9 |
| Rudolph Tanzi | Director | Boston, MA |
| George Alex | Executive Officer | Boston, MA |
| George Alex | Promoter | Boston, MA |
| Rudolph Tanzi | Executive Officer | Boston, MA |
| Rudolph Tanzi | Promoter | Boston, MA |
Other filings by this issuer (1)
More